Research Analysts’ Weekly Ratings Updates for Alnylam Pharmaceuticals (ALNY)

Alnylam Pharmaceuticals (NASDAQ: ALNY) recently received a number of ratings updates from brokerages and research firms:

• 9/8/2026 – Alnylam Pharmaceuticals had its price target raised by Jefferies Financial Group Inc. from $230.00 to $260.00. They now have a “hold” rating on the stock.
• 9/2/2026 – Alnylam Pharmaceuticals had its “buy” rating reaffirmed by HC Wainwright. They now have a $455.00 price target on the stock.
• 8/31/2026 – Alnylam Pharmaceuticals had its “buy” rating reaffirmed by Sanford C. Bernstein.
• 8/31/2026 – Alnylam Pharmaceuticals had its “buy” rating reaffirmed by TD Cowen.
• 8/31/2026 – Alnylam Pharmaceuticals had its “outperform” rating reaffirmed by BMO Capital Markets.
• 8/25/2026 – Alnylam Pharmaceuticals had its “outperform” rating reaffirmed by Sanford C. Bernstein. They now have a $376.00 price target on the stock.
• 8/19/2026 – Alnylam Pharmaceuticals is now covered by BMO Capital Markets. They set an “outperform” rating and a $318.00 price target on the stock.
• 8/18/2026 – Alnylam Pharmaceuticals was upgraded by BMO Capital Markets to “strong-buy”.
• 8/14/2026 – Alnylam Pharmaceuticals had its price target lowered by Wells Fargo & Company from $316.00 to $256.00. They now have an “equal weight” rating on the stock.
• 8/4/2026 – Alnylam Pharmaceuticals had its price target lowered by Truist Financial Corporation from $410.00 to $315.00. They now have a “buy” rating on the stock.
• 8/3/2026 – Alnylam Pharmaceuticals had its price target lowered by Citigroup Inc. from $380.00 to $340.00. They now have a “buy” rating on the stock.
• 8/3/2026 – Alnylam Pharmaceuticals was upgraded by Raymond James Financial, Inc. from “outperform” to “strong-buy”. They now have a $420.00 price target on the stock.
• 8/3/2026 – Alnylam Pharmaceuticals had its price target lowered by Barclays PLC from $527.00 to $450.00. They now have an “overweight” rating on the stock.
• 8/2/2026 – Alnylam Pharmaceuticals was downgraded by Wall Street Zen from “strong-buy” to “hold”.
• 7/31/2026 – Alnylam Pharmaceuticals was upgraded by Weiss Ratings from “hold (c-)” to “hold (c)”.
• 7/31/2026 – Alnylam Pharmaceuticals had its price target lowered by HC Wainwright from $485.00 to $455.00. They now have a “buy” rating on the stock.
• 7/31/2026 – Alnylam Pharmaceuticals had its price target lowered by Royal Bank Of Canada from $445.00 to $350.00. They now have an “outperform” rating on the stock.
• 7/31/2026 – Alnylam Pharmaceuticals had its price target lowered by JPMorgan Chase & Co. from $400.00 to $375.00. They now have an “overweight” rating on the stock.
• 7/31/2026 – Alnylam Pharmaceuticals had its price target lowered by Morgan Stanley from $400.00 to $300.00. They now have an “equal weight” rating on the stock.
• 7/31/2026 – Alnylam Pharmaceuticals had its price target lowered by Oppenheimer Holdings, Inc. from $500.00 to $350.00. They now have an “outperform” rating on the stock.
• 7/31/2026 – Alnylam Pharmaceuticals had its price target lowered by Wells Fargo & Company from $377.00 to $316.00. They now have an “equal weight” rating on the stock.
• 7/31/2026 – Alnylam Pharmaceuticals had its price target lowered by Stifel Nicolaus from $444.00 to $318.00. They now have a “buy” rating on the stock.
• 7/31/2026 – Alnylam Pharmaceuticals had its “buy” rating reaffirmed by Chardan Capital. They now have a $425.00 price target on the stock.
• 7/30/2026 – Alnylam Pharmaceuticals had its price target lowered by Needham & Company LLC from $510.00 to $357.00. They now have a “buy” rating on the stock.
• 7/29/2026 – Alnylam Pharmaceuticals was upgraded by Sanford C. Bernstein to “strong-buy”.
• 7/25/2026 – Alnylam Pharmaceuticals was upgraded by Wall Street Zen from “buy” to “strong-buy”.
• 7/22/2026 – Alnylam Pharmaceuticals had its price target lowered by JPMorgan Chase & Co. from $420.00 to $400.00. They now have an “overweight” rating on the stock.
• 7/14/2026 – Alnylam Pharmaceuticals had its price target lowered by Bank of America Corporation from $460.00 to $410.00. They now have a “buy” rating on the stock.
• 7/13/2026 – Alnylam Pharmaceuticals had its price target lowered by Truist Financial Corporation from $505.00 to $410.00. They now have a “buy” rating on the stock.
• 7/13/2026 – Alnylam Pharmaceuticals had its price target raised by HC Wainwright from $470.00 to $485.00. They now have a “buy” rating on the stock.

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines based on RNA interference (RNAi) technology. RNAi therapies are designed to silence specific genes involved in disease, offering a way to target conditions that may be difficult to treat with conventional drug approaches. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Alnylam’s commercial products include Onpattro (patisiran), Givlaari (givosiran), Oxlumo (lumasiran) and Amvuttra (vutrisiran).